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INTRODUCTION  
September 2015 marked the 15th anniversary of the US Food & Drug Administration (FDA) 
approval of the drug Mifeprex© (generic: mifepristone) for use in medication abortions. Mifeprex 
approval came with requirements that affect both patients and providers and that are far more 
specific than typical requirements for prescription drugs. The package insert (also known as the 
product label) indicates procedures for mifepristone prescribers to follow, based on the regimen 
used during the drug’s pre-approval clinical trials. FDA has not approved any other abortion drugs 
besides Mifeprex. 
In the last 15 years, researchers have studied the safety and efficacy of Mifeprex, as well as the 
medication abortion process as a whole. Their findings reveal that the protocol set out in the 
Mifeprex label does not reflect current practice for safe and effective medication abortion and is in 
need of revision.  
Medication abortion (also called medical abortion) is a safe method of abortion available for the past 
15 years in the US. This paper summarizes the scientific evidence related to the current medication 
abortion process and potential changes to the process that could make it even safer and more 
accessible for patients, as well as policy considerations and directions for future research.  
OVERVIEW OF MEDICATION ABORTION 
Medication abortion is an alternative to vacuum aspiration, which also called surgical abortion, the 
most common precedure for early termination of pregnancy (Weitz et al., 2004). It is sometimes 
called medical abortion, or referred to as RU-486, mifepristone’s early chemical designation. In 2011, 
nearly 240,000 medication abortions were performed in the US, out of 1.06 million total abortions 
(Jones & Jerman, 2014). Since Mifeprex was approved in 2000, medication abortion has accounted 
for a growing share of US abortions, increasing from 14% of non-hospital procedures in 2005 to 
23% in 2011. Ninety percent of clinics that provide abortions offered medication abortions in 2011, 
and 17% of all non-hospital abortion providers offered only medication abortions (Jones & Jerman, 
2014). The cost of medication abortion is generally similar to the cost for a surgical abortion, at 
comparable gestations; in 2011 and 2012, the median charge at similar gestations was $500 for a 
medication abortion and $495 for a surgical abortion (Jerman & Jones, 2014).  
MECHANISM OF ACTION 
In the US, the process of medication abortion generally involves taking two medications: 
Mifeprex, which halts the pregnancy by initiating the breakdown of the endometrium, followed by 
misoprostol, which leads to contractions and emptying of the uterus.  
Mifepristone is a progesterone receptor antagonist. Progesterone is an endogenous steroid 
hormone that is necessary for the menstrual cycle and supports the endometrium during 
pregnancy. Steroid hormones affect cells by binding to specific receptors on the cell surface. A 
steroid antagonist is a substance that competitively binds to the receptor, thereby inhibiting the 
physiological action of the steroid.  
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Mifepristone competes with progesterone at progesterone-receptor sites and inhibits the activity 
of endogenous or exogenous progesterone, initiating the breakdown of the endometrium and 
implanted embryo. This activity is the first step in the abortion (FDA, 2005).  
During the abortion process, mifepristone sensitizes the lining of the uterus to the contraction-
inducing activity of prostaglandins. Prostaglandins and prostaglandin analogs stimulate uterine 
contractions and cause cervical dilation, both leading to emptying of the uterus. During 










Box 1. Key Scientific Terms for Medication Abortion 
Agonist: a molecule that combines with a receptor on a cell to trigger a reaction 
Antagonist: a biological structure or chemical agent that interferes with the 
physiological action of another agent 
Ectopic pregnancy: a gestation elsewhere than in the uterus; often occurring in the 
fallopian tube; presents with abdominal pain, fainting, and/or vaginal bleeding. 
Endogenous: developed or originating within the body or arising from causes within 
the body  
Exogenous: developed or originating outside the body 
Receptor: a molecular structure within a cell or on the surface characterized by 
selective binding of a specific substance and a specific physiologic effect that 
accompanies the binding 
Progesterone: a steroid hormone produced in the ovary; prepares and maintains the 
uterus for pregnancy 
Prostglandin: mediator of physiological processes, including speeding evacuation of the 
uterus by stimulating contractions 
Teratogenic: tending to produce anomalies of formation, the development of 
malformations, or serious deviations from the normal type of organism 
Adapted from biology-online.org 
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Figure 1. How Agonists and Antagonists Work 
 
Source: Antranik.org, 2012 
 
SAFETY AND EFFICACY 
Medication abortion is a safe and effective process. The CDC began collecting data on mortality 
from medication abortion in 1997 and noted no deaths among over 6,000 women using 
mifepristone during clinical trials (Beal, 2007). Although mifepristone’s safety record has remained 
strong overall, in the first years after its approval, several women who had undergone medication 
abortion in the US died as a result of infection (see “GAO Review of FDA Approval Process for 
Mifeprex” section on page 8 for further discussion). When these deaths are included in the total 
abortion surveillance data, they bring the mortality rate to approximately 1 per 100,000, which is 
slightly higher than the mortality rate for surgical abortion but significantly lower than the maternal 
mortality rate for women bringing their pregnancies to term (9.8 per 100,000) (Beal, 2007).  
Studies of medication abortion find that between 95% and 98% of cases result in complete 
termination. These outcomes may vary slightly depending on the exact regimen used (e.g., dosage 
of Mifeprex, timing of misoprostol) but are similar to success rates for surgical abortion (Bartz & 
Goldberg, 2009). The American College of Obstetricians and Gynecologists (ACOG) reports the 
success rate of medication abortion as 95%, compared to 99% for surgical abortion (Committee 
on Practice Bulletins – Gynecology and the Society of Family Planning, 2014). 
After taking both mifepristone and misoprostol, women can expect heavy bleeding and cramping. 
These are both normal reactions to the medications, although women may seek medical attention 
if they are severe. Additional medical interventions can include antibiotics for infection and 
aspiration or curettage for bleeding or for ongoing pregnancies if necessary.  
A study of abortion-related insurance claims from California’s Medicaid program found that 5.2% 
of more than 11,000 women who received medication abortions sought care in an emergency 
department, and the vast majority of their conditions were minor and expected. The authors 
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report that only 0.31% of the women who received medication abortions experienced serious 
unexpected adverse events, such as hemorrhage, that required hospital admission, surgery, or 
blood transfusion, and fewer than one percent (0.87%) had incomplete abortions (Upadhyay et al., 
2015). A separate study of more than 200,000 medication abortions provided between 2009 and 
2010 at Planned Parenthood health centers found significant adverse events in 0.16% of cases, 
including one death from an undiagnosed ectopic pregnancy, and ongoing intrauterine pregnancies 
in 0.50% of cases. The authors noted that the count of ongoing pregnancies does not include cases 
in which an ongoing pregnancy was detected in a follow-up evaluation and successfully treated 
with a repeat does of misoprostol (Cleland et al., 2013).    
There are very few specific medical contraindications to medication abortion, which means that 
medication abortion can be an appropriate option for most women. Contraindications include: 
previous allergic reaction to one of the drugs used, chronic adrenal failure, severe anemia, having 
an IUD in place, and known/suspected ectopic pregnancy (Bartz & Goldberg, 2009; Committee 




Box 2. Other Medication Abortion Drugs 
While the mifepristone-misoprostol combination is widely used in the US, other 
medications may be used for medication abortions in other countries, or in rare 
circumstances, in the US. In several countries, methotrexate is often the first step in 
the medication abortion process. Although methotrexate is very effective (up to 97% 
of women successfully abort if methotrexate is followed by misoprostol), it also has 
significant drawbacks. Because methotrexate is teratogenic, surgical follow-up must be 
performed if there is an incomplete abortion procedure. Women may also have to wait 
up to four weeks to determine if their abortions are complete, by which point, surgical 
intervention may become more intensive and difficult for both patients and providers 
(Bartz & Goldberg, 2009). In China, ethacridine lactate (via intra-amniotic injection) is 
the first step in the medication abortion process and is followed by misoprostol; 
however, a recent study found that the mifepristone-misoprostol regimen is preferable 
because of fewer side effects and a higher success rate (Hou et al., 2011).  
In addition to misoprostol, several other prostaglandin analogs can be used for the 
second step in the process. The most commonly studied include cervagem, gemeprost, 
carboprost, and sulprostone (Lalitkumar, Bygdeman, & Gemzell-Danielsson, 2007). A 
Danish study comparing gemeprost and misoprostol found both to be equally effective, 
with a 99% complete abortion rate (Lipp, 2008). Another study comparing cervagem – 
which was widely used in the UK before misoprostol became available – with 
misoprostol found no significant differences in the efficacy of the two drugs (Dodd & 
Crowther, 2006). See “Misoprostol-Only Abortions” (page 25) for further discussion. 
Jacobs Institute of Women’s Health Bridging the Divide | 6  
 
FDA DRUG APPROVAL PROCESS  
In general, it takes approximately eight to nine years to bring a drug to market, from the first 
experimental animal tests to the final approved product. The drug manufacturer writes (and owns) 
the product label, but FDA must approve the exact language used on the label; this process often 
involves negotiation between the manufacturer and FDA. Once approved by FDA, the label 
governs the information that can be distributed by the sponsor, including materials distributed by 
industry and sales representatives.  
Once a drug has been developed and tested in clinical trials, the drug manufacturer must submit the 
drug for approval by FDA. In general, the process for approval of a new drug is as follows:  
“Before a drug can be marketed in the United States, the drug sponsor must submit a new 
drug application (NDA) to FDA containing data demonstrating the safety and efficacy of the 
drug. FDA reviews the NDA to determine whether the drug’s benefits outweigh its risks. 
Once FDA completes its review, the agency issues an action letter 1  in which it either 
approves the drug as safe and effective for its intended use (approval letter), informs the 
sponsor that the drug is likely to be approved once the deficiencies FDA has identified are 
resolved (approvable letter), or indicates that approval cannot be obtained without 
substantial additional information (not approvable letter). If FDA issues an approvable or 
not approvable letter, a subsequent review cycle can begin once the sponsor has addressed 
the issues FDA identified.” (GAO, 2008) 
All information distributed by drug manufacturers must be “on-label” – consistent with the drug 
label. However, providers may prescribe a drug “off-label” after it is approved for use in the US. 
Off-label prescribing is a common phenomenon across many types of care, and different protocols 
or uses often arise after a drug is approved for a specific condition. For example, albuterol is a 
rescue medicine prescribed for asthma but is often prescribed off-label for chronic obstructive 
pulmonary disease (COPD) (Radley, Finkelstein, & Stafford, 2006). In the US, between 10% and 
21% of prescriptions are given off-label (Fitzgerald & O’Malley, 2014; Radley, Finkelstein, & 
Stafford, 2006).  
FDA APPROVAL OF MIFEPREX 
Mifepristone was first approved for use in France in 1988 (Jones & Henshaw, 2002). In the US, 
Danco Laboratories, LLC first submitted Mifeprex for FDA approval in 1996, after a long delay 
and opposition by anti-abortion advocates and policy-makers. The approval process took 
approximately four years, from the submission of the initial new drug application (NDA) in 1996 
through three review cycles and ultimate approval (see Table 1) (GAO, 2008). Bringing this 
                                                 
1 FDA no longer uses the format of the approval/approvable/not approvable letter. Instead, 
applicants receive a complete response letter, the process for which is outlined here: 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.110. 
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product to the US required a collaborative effort between researchers, industry, and pro-choice 
advocates. 
 
Table 1: Timeline of Key Events in FDA's Approval of Mifeprex 
Date Event 
First Review Cycle 
March 1996 The sponsor submitted a new drug application (NDA) for the use of 
Mifeprex in combination with the drug misoprostol for the medical 
termination of intrauterine pregnancy. 
July 1996 FDA Reproductive Health Drugs Advisory Committee meeting. 
September 1996 FDA issued an approvable letter listing issues that the sponsor needed 
to address before the application could be approved.  
Second Review Cycle 
August 1999 After delays securing a manufacturer, the sponsor completed its 
responses to FDA’s 1996 approvable letter. 
February 2000 FDA issued a second approvable letter, listing issues that the sponsor 
needed to address prior to approval.  
Third Review Cycle 
March 2000 The sponsor completed its responses to FDA’s second approvable 
letter. 
September 2000 FDA approved Mifeprex under the restricted distribution provision of 
Subpart H. 
November 2000 Distribution of Mifeprex began in the United States. 
Source: GAO, 2008 
 
During the third and final review cycle for Mifeprex, FDA determined that the drug’s approval 
process met the criteria for the process known as Subpart H, from Title 21, Part 314, Subpart H  
of the Code of Federal Regulations, “Accelerated Approval of New Drugs for Serious or Life-
Threatening Illnesses” (CFR - Code of Federal Regulations Title 21, 2015). Subpart H regulations 
for approval generally apply if a drug meets one of the following two criteria: (1) “approval with 
restrictions to assure safe use” or (2) “approval based on a surrogate endpoint or on an effect on a 
clinical endpoint other than survival or irreversible morbidity” (CFR - Code of Federal 
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Regulations Title 21, 2015). FDA has applied the second provision mostly for cancer or 
HIV/AIDS drugs (GAO, 2008). In the case of Mifeprex, the first condition applied because FDA 
concluded that the drug could only be used safely if distribution was limited to qualified clinicians. 
In a review of the mifepristone approval process, the Government Accountability Office (GAO) 
noted that this determination is generally consistent with the approval process for other Subpart 
H drugs and that FDA’s postmarket oversight of Mifeprex has also been consistent with oversight 
of other Subpart H drugs (GAO, 2008). It is important to note that Mifeprex did not undergo an 
expedited review process, which occurs for drugs meeting the second criterion for Subpart H.  
As part of the approval conditions established in 1996, physicians who intend to offer medication 
abortion must sign a prescriber’s agreement and must meet certain criteria, including the ability to 
perform surgical interventions  (i.e., vacuum aspiration, also known as dilation and evaucation, or 
D&E) to manage complications (GAO, 2008). Patients must also sign a patient agreement before 
providers can give patients the medication. Both agreements are included in the appendix.  
FDA no longer uses the Subpart H process. Instead, for drugs that formerly met the criteria for 
the Subpart H designation, FDA uses the Risk Evaluation and Mitigation Strategy (REMS) and 
Elements to Assure Safe Use (ETASU); further details about these mechanisms are included in 
“Advocacy for Label Change” on page 31.  
GAO REVIEW OF FDA APPROVAL PROCESS FOR MIFEPREX 
In the six years following FDA’s approval of Mifeprex four women contracted fatal infections 
caused by a bacterium called Clostridium sordelli after medication abortions. (A fifth woman died of 
infection from a different but related bacteria, Clostridium perfringens, during the same time period, 
and an additional fatality from C. sordelli occurred in 2007.) Congress tasked the GAO with 
reviewing the approval and oversight of the drug, with particular regard to the infection deaths. 
The GAO report concluded that the approval process had been consistent with the general FDA 
approval process for similar drugs and noted that FDA itself had concluded that evidence does 
not indicate that Mifeprex caused the fatal infections (GAO, 2008). However, GAO did note that:  
“… in the six cases of death due to infection, the women used a regimen of Mifeprex 
and misoprostol that has not been approved by FDA. FDA has stated that it is aware 
that many health care providers use modified regimens, and while some of the 
regimens have been described in the medical literature, FDA has not evaluated the 
safety and effectiveness of any other regimen than the one described in the drug’s 
approved labeling.” (GAO, 2008) 
Other research studies support these findings about the clostridium deaths.  
The women who died were diagnosed with toxic shock syndrome (TSS). The infection itself is not 
always fatal, except in cases that progress to TSS (Beal, 2007). Incidence of C. sordelli infection is 
very rare, at a rate of 1 infection per 100,000 people. Up through 2001, 10 cases of TSS from 
genital tract infections (unrelated to abortion) were reported in the literature, as were 28 cases of 
obstetric and gynecologic infections with C. sordelli in healthy women either postpartum, after 
miscarriage, or following induced abortion (Beal, 2007). Tests of the Mifeprex lots used in the 
fatal cases revealed no clostridium contamination. All six women who contracted fatal infections 
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after having a medication abortion had received the then-current regimen of 800 µg vaginal 
misoprostol, self-administered (Beal, 2007). The Mifeprex label now includes a boxed warning 
stating, “Serious and sometimes fatal infections and bleeding occur very rarely following 
spontaneous, surgical, and medical abortion, including following Mifeprex use” (FDA, 2005). 
Some researchers concluded that the administration route (vaginal) was potentially the source of 
the infections, despite the fact that there is little definitive evidence to support this position. 
However, Planned Parenthood health centers changed their practice guidelines for route of 
administration from vaginal to buccal and added universal antibiotic prophylaxis, and the death 
rate subsequently declined significantly, dropping from 1.37 per 100,000 to 0 per 100,000 (Trussell 
et al., 2014). There have been no reported clostridium-related deaths at Planned Parenthood in 
women undergoing medication abortion since the protocol change (Trussell et al., 2014), although 
a 2011 FDA Postmarketing Adverse Events Summary reports two sepsis deaths in addition to the 
original six, with one of the new cases involving vaginal misoprostol and the other buccal 
misoprostol (FDA, 2011). It is not possible to determine whether the death rate improved 
because of the change in route of administration or the administration of prophylactic antibiotics, 
or due to some other factor such as a change in the bacteria present in the environment.  
 MEDICATION ABORTION PROCESS: STATE OF THE EVIDENCE 
“It is highly unusual for the FDA to include such a restrictive regimen on a drug label. No 
other drug with a comparable safety profile carries a remotely similar label. Numerous drugs 
sold over the counter in the United States—such as acetaminophen, anti-histamines, and 
nonsteroidal anti-inflammatories—result in considerably more adverse events, including 
death, than mifepristone.” (Coeytaux, Hessini, & Allina, 2015) 
FDA-APPROVED LABEL  
The FDA-approved Mifeprex label specifies that patients must have intrauterine pregnancies of 
up to 49 days gestation, and that providers may determine pregnancy duration from menstrual 
history and clinical exam, with an ultrasonographic scan used if gestational duration is uncertain or 
ectopic pregnancy suspected (FDA, 2005). Mifeprex is supplied only to licensed physicians who 
sign and return a Prescriber’s Agreement, and patients must sign a Patient Agreement (see 
Appendices A and B). 
The label specifies that treatment requires three office visits and that “Mifeprex may be 
administered only in a clinic, medical office, or hospital, by or under the supervision of a 
physician.” On the first visit, the patient signs the patient agreement and receives a 600 mg oral 
dose of Mifeprex. On the second visit two days later, she takes 400 µg of misoprostol orally. On 
the third visit approximately 14 days after the first one, she returns for a follow-up visit at which 
complete termination of the pregnancy is confirmed by clinical examination or ultrasonographic 
scan (FDA, 2005). In states that require a waiting period between a first visit and the initiation of 
medication abortion, following the FDA label’s protocol requires four visits.  
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Table 2: FDA Label Specifications and Off-Label Variations 
 On-Label Regimen Evidence-Based Variations 
Provider 
Physicians and providers 
under physician supervision 
Physicians and mid-level providers* with or 
without supervision**; physicians via 
telemedicine  
Timing 
Up to 49 days from LMP 
(last menstrual period) 
Up to 63 days from LMP in wide use; 
evidence supports up to 70 days  
Use of 
Mifepristone 
Day 1: 600 mg orally at 
clinical site 
200 mg orally, may be taken at home 
Use of 
Misoprostol 
Day 3: 400 µg orally at 
clinical site  
Typically taken at home; interval between 
mifepristone and misoprostol varies; 800 µg 
dose is common, and is generally administered 
buccally, sublingually, or vaginally 
Follow-Up 
Day 14: Confirm complete 
abortion 
Follow up after 7-14 days; some providers 
offer lab follow-up or remote follow-up 
alternatives; self-assessment offered in some 
countries 
* Mid-level providers include nurse practitioners (NPs), certified nurse-midwives (CNMs), and physician 
assistants (PAs); new WHO recommendations include nurses as well. 
** As permitted by state laws, and under the Provider Agreement 
 
EVIDENCE-BASED PROTOCOLS FOR MEDICATION ABORTION 
US providers began adopting evidence-based regimens that varied from the FDA label soon after 
the agency approved Mifeprex. These variations – technically considered “off-label” – do not 
adhere to all the specifications of the FDA label but are supported by substantial evidence. 
(Describing these variations as “evidence-based” is not meant to suggest that the FDA label is not 
based on evidence; rather, it serves to distinguish between the FDA-approved regimen and the 
off-label regimens, which do not currently  have FDA approval but do have a substantial evidence 
base from trials conducted after Mifeprex’s approval.) 
DOSAGE 
The use of 200 mg of mifepristone, rather than the 600 mg specified in the FDA label, is 
recommended by the World Health Organization, the American College of Obstetricians and 
Gynecologists (ACOG), the Society of Family Planning, and the Planned Parenthood Federation 
of America (Cleland & Smith, 2015). A 2014 ACOG practice bulletin notes that regimens using 
200 mg of mifepristone “have similar efficacy and lower costs” than those involving 600 mg. It 
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also states, “Based on efficacy and the adverse effect profile, evidence-based protocols for 
medical abortion are superior to the FDA-approved regimen” (Committee on Practice 
Bulletins—Gynecology and the Society of Family Planning, 2014). The use of 800 µg of 
misoprostol, rather than the 400 µg in the FDA label, is also common (Committee on Practice 
Bulletins—Gynecology and the Society of Family Planning, 2014).  
TIME INTERVALS BETWEEN MEDICATIONS 
Shortening the interval between administration of mifepristone and misoprostol improves 
flexibility for patients and clinicians and reduces the duration of medication abortions, and many 
studies have demonstrated the safety and efficacy of intervals shorter than the 48 hours specified 
on the FDA label (Shaw et al., 2013; Wedisinghe & Elsandabesee, 2010). In 2006, a systematic 
review of the literature concluded that the interval could be reduced from 48 hours to 24 hours 
without a loss of efficacy (Schaff, 2006). A 2010 systematic review and meta-analysis of studies 
with intervals from 0 – 72 hours concluded that differences in overall efficacy were not statistically 
significant between longer and shorter intervals, but that there was a trend toward a lower success 




ROUTE OF ADMINISTRATION OF MISOPROSTOL 
Misoprostol can be taken orally (swallowed), buccally (held in the cheek to dissolve), sublingually 
(held under the tongue to dissolve), or vaginally (manually inserted into the vagina). The route of 
administration influences how the drug is metabolized and the peak concentration it can reach in 
the bloodstream. When compared to oral and vaginal administration, sublingual misoprostol 
reaches the highest peak concentration and has the greatest bioavailability (Tang & Ho, 2008). 
The FDA-approved label specifies oral administration. Vaginal administration was common in 
the years immediately following Mifeprex’s approval (Winikoff et al., 2008). Clinical trials found 
that oral and buccal administration are similarly effective for pregnancies of up to 49 days 
(Winikoff et al., 2008), and buccal and sublingual routes are equally effective in women with 
pregnancies of up to 63 days (Chai, Wong, & Ho, 2013).  
Box 3. Routes of Drug Administration in Medication Abortion 
Buccal: held between the gum and cheek to dissolve; remainder swallowed after 30 
minutes 
Oral: swallowed; common with many pills 
Sublingual: held under the tongue to dissolve; remainder swallowed after 30 minutes 
Vaginal: inserted into the vagina  
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GESTATIONAL LIMITS 
While the FDA label specifies that medication abortions may be performed for pregnancies of 
up to 49 days since the last menstrual period, several large studies demonstrate the safety and 
efficacy of the evidence-based protocol for gestations of up to 70 days (Abbas, Chong, & 
Raymond, 2015; Bracken, Dabash, et al., 2014; Sanhueza Smith et al., 2015; Winikoff et al., 
2012). The National Abortion Federation’s Clinical Policy Guidelines give 70 days as the limit 
for medication abortions using mifepristone and vaginal, buccal, or sublingual misoprostol 
(while the oral route of misoprostol can be used up to 63 days) (National Abortion Federation, 
2015). Planned Parenthood Federation of America (PPFA) sets the gestational limit for 
medication abortion at 63 days, except in states that require providers to adhere to the FDA 
label, in which case the limit is 49 days. However, affiliates may request a waiver from PPFA to 
extend the limit to 70 days gestation; many affiliates have taken advantage of this option 
(Planned Parenthood officials, personal communication, 2015).  
Outside the US, World Health Organization (WHO) recommendations frequently guide clinical 
practice. WHO recommendations on medication abortion regarding gestional misoprostol dose, 
subsequent doses should be 400 µg and repeated every three hours up to four additional doses 
(WHO, 2012). The UK’s Royal College of Obstetricians & Gynaecologists recommends 
protocols involving repeated misoprostol dosing for pregnancies of 9-13 weeks (63 – 91 days) 
(Royal College of Obstetricians & Gynaecologists, 2011). 
HOME USE OF MISOPROSTOL 
The FDA label specifies that women should return to their providers 48 hours after mifepristone 
administration to receive misoprostol in person, but as early as 2001, 83% of surveyed National 
Abortion Federation (NAF) members reported they were giving women misoprostol to take at 
home (Wiegerinck et al., 2008). A 2007 review found ample evidence that home use of 
misoprostol is safe and effective, and reported that the second visit for misoprostol administration 
had been replaced by home use in the US and UK (Clark, Gold, et al., 2007). Recent large studies 
have investigated evidence-based protocols that include home use of misoprostol and confirmed 
high rates of safety and efficacy (Cleland et al., 2013; Gatter, Cleland, & Nucatola, 2015). 
NON-PHYSICIAN PROVIDERS 
The FDA label requires that mifepristone be administered “by or under the supervision of a 
physician” (FDA, 2005). Attorneys general or health departments in some states have 
interpreted this clause as allowing mid-level providers (MLPs) such as nurse practitioners (NPs), 
certified nurse-midwives (CNMs), and physician assistants (PAs) to provide medication abortion; 
one state, California, has passed a law authorizing MLPs to provide medication abortions 
(Samora & Leslie, 2007; Weitz et al., 2013). MLPs, also referred to as advanced-practice 
clinicians, are increasingly involved in medication abortions in Denmark, France, Great Britain, 
and Sweden; in the US at some clinics, MLPs handle the entire medication abortion process 
(Yarnall, Swica, & Winikoff, 2009). New guidelines from the World Health Organization 
recommend that nurses and midwives (as well as advanced associate clinicians and physicians) 
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provide medication abortions (WHO, 2015). The National Abortion Federation’s Clinical Policy 
Guidelines state, “Abortion will be provided by licensed practitioners. This category is intended 
to include physicians from various specialties as well as nurse midwives, nurse practitioners, 
physician assistants, registered nurses, and other health professionals” (NAF, 2015). 
Medication abortions result in similar safety and efficacy profiles for both MLPs and physicians 
(Barnard et al., 2015). The primary difference between medication abortions provided by MLPs 
and those provided by physicians is that MLPs are more likely to seek second opinions on their 
ultrasound assessments during pregnancy evaluation than their physician counterparts; however, 
the frequency of these consultations has been shown to decrease over time, as MLPs gain 
experience with ultrasound dating (Kopp Kallner et al., 2015; Warriner et al., 2011). Studies in 
Mexico, Nepal, India, and Sweden show no difference in rates of incomplete abortion or 
abortion failure between MLPs and physicians (Barnard et al., 2015; Ngo, Park, & Free, 2013; 
Olavarrieta et al., 2015; Renner, Brahmi, & Kapp, 2013). It is important to note that most 
available data on this topic comes from settings outside of the US. Areas in the US where 
abortion providers are scarce may mirror the settings studied in Mexico, Nepal, and India, and 
high-resource settings in the US may be similar to those studied in Sweden, but further research 
in US settings could provide more direct comparisons.  
Ensuring that MLPs have the legal authority and training to provide medication abortions can 
increase access to safe abortion services in areas with few physicians, such as rural areas where 
advanced practice clinicians but not obstetricians or gynecologists (OB/GYNs) are located (Foster 
et al., 2015; Taylor, Safriet, & Weitz, 2009). It can also enhance the cost-effectiveness of abortion 
care and allow providers to offer services to more women (Yarnall, Swica, & Winikoff, 2009). 
EVOLVING EVIDENCE FOR ADDITIONAL VARIATIONS 
Several other variations, some of which are already used widely in other countries or by some US 
providers, have the potential to reduce barriers to medication abortion for US women. One 
especially noteworthy recommendation comes from the World Health Organization, whose new 
guidelines recommend that women with pregnancies of up to 63 days be allowed to manage 
mifepristone and misoprostol medication without direct provider supervision and to self-assess 
abortion completion, though only “in circumstances where women have a source of accurate 
information and access to a health-care provider should they need or want it at any stage of the 
process” (WHO, 2015). 
HOME USE OF MIFEPRISTONE  
The FDA-approved label specifies that women take mifepristone in a clinic, medical office, or 
hospital. Allowing women to instead take mifepristone (in addition to misoprostol) at the time 
and place of their choosing can increase autonomy and privacy (Chong et al., 2015) and reduce 
logistical barriers. Women likely prefer to schedule medication abortions so they can experience 
the bleeding and cramping while they are not at work or school; however, these days may not 
align with the days when providers have appointments available. Timing can be especially 
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problematic for women without access to paid sick days, a group disproportionately composed 
of low-income workers (Bureau of Labor Statistics, 2015). 
Raymond and colleagues note that requiring mifepristone to be administered only in a clinical 
setting is without medical justification; because the drug’s pharmacologic action occurs several 
hours after ingestion, they point out that patients are nearly always elsewhere by the time any 
effects might occur (Raymond, Grossman, et al., 2015). 
Several studies have tested protocols that allow women to leave their first appointments with 
mifepristone and instructions for taking it at a later time, and have reported no differences in 
efficacy or complications. A 2011 review considered randomized trials and prospective cohort 
studies from several different countries, comparing home use of mifepristone to clinic-based 
protocols, and found no evidence of difference in effectiveness (Ngo et. al, 2011). More recent 
studies include one involving 400 women who received care at six US Planned Parenthood 
centers and were given the choice of taking mifepristone at the clinic or at home (within one 
week of their visit, and within the 63-day gestation window). Rates of success did not differ 
between the home and clinic groups; none of the home users reported taking mifepristone after 
the 63-day window; and home users reported missing less work and school (Chong et al., 2015).  
REDUCING BARRIERS POSED BY FIRST AND FOLLOW-UP VISITS  
While the second visit specified under the FDA label is easily eliminated by giving women 
misoprostol to take at home, eliminating or simplifying the protocol’s first and follow-up visits 
requires more consideration. Further simplifications can improve access for women in areas 
without abortion providers as well as those who live near abortion providers and find multiple 
office visits logistically or financially challenging.  
FIRST VISIT 
The FDA-approved label specifies that mifepristone must be administered “by or under the 
supervision of a physician, able to assess the gestational age of an embryo and to diagnose 
ectopic pregnancies,” but it does not specify how providers should make these determinations 
(FDA, 2005). Many providers use ultrasonography to confirm intrauterine pregnancy and 
ascertain gestational duration, but routine use of pre- and post-abortion sonograms can raise 
costs and limit access (Clark, Panton, et al., 2007). Practitioners without ultrasound equipment 
on site may be more likely to offer medication abortions if they feel they can do so without 
reliance on routine ultrasonography (Fielding, Schaff, & Nam, 2002). Guidelines from the 
American College of Obstetricians and Gynecologists, the National Abortion Federation, and 
the Royal College of Obstetricians and Gynecologists note that ultrasound is not required for 
first-trimester medication abortions (NAF 2015; Raymond, Grossman, et al., 2015). 
Ultrasound confirmation of gestational age is currently required for Planned Parenthood 
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DETERMINING GESTATIONAL DURATION 
Clark, Panton, and colleagues (2007) recommend that a woman’s report of her last menstrual 
period (LMP) combined with a bimanual pelvic examination can be used in most cases to date 
the gestation. Following a chart review of medication abortion patients, they concluded that it 
may be safe and efficient to reserve sonography for cases in which: LMP dating may be 
inaccurate; an examination suggests a gestation beyond the medication abortion cutoff date; or 
an exam or recent medical history suggests an elevated risk of ectopic pregnancy (Clark, 
Panton, et al., 2007). A 2007 review found, “Women’s report of their LMP, in combination 
with bimanual examination, can safely be substituted for routine sonography in the absence of 
significant discrepancies or inconsistencies for gestational dating before most cases of medical 
abortion” (Clark, Gold, et al., 2007). A 2011 review concluded that clinicians can reasonably 
estimate gestational duration from reported LMP and a physical examination (Kaneshiro et al., 
2011). More recently, a 2014 review compared LMP to ultrasound for determining gestational 
duration, and concluded that women’s report of LMP can be used to determine gestation for 
up to 63 days, although the authors recommend further study comparing reported LMP only 
to a physical exam plus LMP (Schonberg et al., 2014). Such future research could determine 
whether using LMP alone for gestational dating is as accurate as the combination of LMP and 
a physical exam.  
For determining gestational duration, a 10-site US study involving women specifically seeking 
medication abortions found pregnancy dating based on women’s LMP reports to be nearly as 
accurate as dating based on ultrasonography. The study authors recorded women’s reported 
LMP and then compared those dates to ultrasound findings in order to determine whether 
LMP dating and ultrasound would concur in identifying women whose pregnancies were of up 
to 63 days. Of the more than 3,000 women certain of their LMP dates, only 2.4% would have 
been offered medication abortions when the determination was based on LMP alone but not 
when it was based on ultrasound. When reported LMP was combined with physician 
examination, only 1.6% of participants would have been offered a medication abortion that 
they would not have been eligible for based on ultrasound findings. Given that the 
mifepristone-misoprostol combination remains highly effective for several weeks after the 63-
day cutoff, the authors note, there is a high likelihood that the treatment would still work in 
any women who received it based on LMP-only dating that may have underestimated 
gestational duration (Bracken et al., 2011). However, Raymond and Bracken (2015) caution 
that providing medication abortion to women beyond the gestational limit could result in 
complications or the need for a later, higher-risk procedure, and that expelling a fetus that is 
more developed than expected could be emotionally or physically traumatic. 
Raymond and colleagues suggest that testing women’s blood for levels of human chorionic 
gonadotropin (hCG) – a hormone women’s bodies produce during pregnancy – could also 
provide assurance of appropriate gestational duration. Because hCG production rises during 
the first trimester before falling and plateauing, the authors comment, “It seems possible that a 
concentration cutoff could be identified that in combination with menstrual history could 
identify a pregnancy of less than 70 days” (Raymond, Grossman, et al., 2015).  
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IDENTIFYING ECTOPIC PREGNANCIES 
The mifepristone-misoprostol combination is not effective for terminating ectopic 
pregnancies, and many providers may use ultrasound routinely before medication abortions to 
ensure that pregnancies are located inside the uterus. However, when used for this kind of 
routine screening, ultrasonography may miss up to 30% of ectopic pregnancies (Clark, Gold, 
et al., 2007). Bracken and colleagues instead recommend, “Screening for ectopic pregnancies 
on the basis of risk factors, symptoms and bimanual examinations may be more effective” 
(Bracken et al., 2011). Women are at greater risk of ectopic pregnancy if they have previously 
had an ectopic pregnancy, pelvic inflammatory disease, sexually transmitted disease, tubal 
surgery, pelvic or abdominal surgery, infertility, or endometriosis (ACOG, 2011). In the US 
population as a whole, approximately 2% of pregnancies are ectopic; among patients seeking 
abortion, it has been found to be as low as 0.2% (Raymond, Grossman, et al., 2015).  
ASCERTAINING RH STATUS 
The first visit also typically involves testing for Rh factor, a protein that can be present on red 
blood cells. Women who are Rh-negative but carrying Rh-positive fetuses can become Rh-
sensitized, which can lead to complications for their future children, specifically: severe anemia 
in utero. To prevent this, Rh-negative pregnant women receive Rh immunoglobulin (ACOG, 
2013), though an evidence base is lacking for Rh immunoglobulin treatment in women 
receiving first-trimester abortions (Raymond, Grossman, et al., 2015). Raymond, Grossman, 
and colleagues (2015) note that 85% of US women are Rh-positive, and many women 
receiving abortions either know their Rh type or could get tested at a commercial laboratory.  
FOLLOW-UP VISIT 
Per the FDA-approved label, a third visit 14 days after mifepristone administration allows the 
provider to confirm that the pregnancy was completely terminated. (Women are instructed to 
seek medical attention before their follow-up visits if they experience any problem, such as 
severe bleeding.) Several of the studies on medication abortion variations involved some 
flexibility in the timing of follow-up, with visits scheduled for between one and two weeks 
after mifepristone administration (e.g., Chong et al., 2015; Gatter, Cleland, & Nucatola, 2015; 
Winikoff et al., 2008). National Abortion Federation guidelines state, “Follow-up evaluation 
should be scheduled for 7-14 days after starting medical abortion” (NAF, 2015). 
The mifepristone-misoprostol combination is highly effective, but the small percentage of 
continuing pregnancies must be detected quickly so that women can receive additional 
treatment without delay – because in some cases, continuing pregnancies can be advanced 
enough to require higher-risk treatments or to extend past a state’s gestational limit for 
abortion or past the limits to which local providers adhere. Additional treatment can take the 
form of aspiration, surgical completion, or additional misoprostol (Committee on Practice 
Bulletins—Gynecology and the Society of Family Planning, 2014; Li et al., 2008; Reeves, 
Kudva, & Creinin, 2008; WHO 2012). Any ectopic pregnancies not detected before the 
medication abortion will require prompt medical attention.  
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Studies have found that large percentages of women do not complete their follow-up visits 
after medication abortion. Loss to follow-up rates vary, ranging from 16-45% (Gatter, Cleland, 
& Nucatola, 2015), and providers’ office staffs devote considerable time to attempting to reach 
women who do not keep their follow-up appointments (Pocius et al., 2015). High rates of loss 
to follow-up also make research challenging, because researchers are unlikely to know 
outcomes for patients who do not attend follow-up visits or complete other scheduled follow-
up communications. 
Researchers are exploring and comparing different methods for confirming the completion of 
medication abortions. These methods include those that can be used at follow-up visits as well 
as alternatives that do not require women to make additional clinic visits. The availability of 
such alternatives has the potential to increase abortion access by making medication abortion 
available in additional locations and to reduce the barriers that patients currently face. 
The WHO guidelines advise, “There is no medical need for a routine follow-up visit following 
uncomplicated surgical abortion or medical abortion using mifepristone followed by misoprostol. 
However, women should be advised that additional services are available to them if needed or 
desired” (WHO, 2012). Currently, the follow-up visit is optional at UK provider Marie Stopes 
International, and approximately half of patients go for these visits (Clark, Gold, et al., 2007). 
 
Table 3: Methods for Confirming Complete Medication Abortion 
Method Description Considerations 
Ultrasound Transvaginal ultrasound typically used 
Equipment is expensive, and 
not all providers have it on-site
Physical exam 
May include bimanual and/or speculum 
examination 
Requires follow-up visit 
Measurement 
of hCG 
Human chorionic gonadotropin (hCG) is 
a hormone produced during pregnancy 
 
      Serum hCG 
Blood is drawn and analyzed before and 
after mifepristone administration 
Can be done at local commercial 
labs or clinicians’ offices 
      Urine hCG 
High-sensitivity, low-sensitivity, or semi-
quantitative tests 
Women can perform the tests 
at home or in clinicians’ offices
Discussion 
with clinician 
Medical history, questions about still 
feeling pregnant/having passed the 
pregnancy, etc. 
Can be done in person or  
by phone 
Questionnaire 
Questions about symptoms experienced, 
still feeling pregnant, etc.  
Can be administered by non-
clinicians, e.g., call center staff 
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METHODS FOR CONFIRMING COMPLETE MEDICATION ABORTION  
In the US, confirmation of complete medication abortion typically involves either an 
ultrasound or blood tests comparing a new serum hCG measurement with one that was taken 
on the first visit (Pocius et al., 2015). Other methods – including urine hCG measurement, 
physical examination, and a discussion of symptoms – can be used in addition to or instead of 
the ultrasound or serum hCG measurement. Research into alternatives is ongoing, and some 
providers have updated their protocols as new studies have been published. This section 
briefly describes the different methods for determining abortion completion, and the following 
sections summarize some of the key studies incorporating these methods into alternative 
follow-up regimens. 
Ultrasound: Transvaginal ultrasounds are commonly performed one week after treatment 
(Horning et al., 2012). 
Physical exam: Physician assessment can include bimanual or speculum exams or both (Clark 
et al., 2010). Providers typically also ask women about bleeding and other symptoms they have 
experienced. 
Blood tests: Studies have demonstrated that comparing baseline and post-abortion levels of 
serum hCG can reliably indicate successful medication abortions (Dunn et al., 2015). 
According to ACOG, a serum hCG level decrease of at least 80% six or seven days after 
mifepristone administration indicates a successful abortion (Committee on Practice 
Bulletins—Gynecology and the Society of Family Planning, 2014).  
Home urine tests: HCG is also present in pregnant women’s urine, and women can use 
inexpensive urine tests at home to measure hCG. However, although hCG levels drop after 
termination of pregnancy, low levels of hCG can persist for a month or longer (Godfrey et al., 
2007). Some of the studies involving urine pregnancy tests have used high-sensitivity tests, 
which can detect hCG at low concentrations (25–50 mIU/mL), while others have used low-
sensitivity tests (1000 mIU/mL). Low-sensitivity tests can be used sooner after a medication 
abortion (Godfrey et al., 2007), because they will not detect the low levels of hCG that may 
still be present even though the woman is no longer pregnant.  
Another option for urine tests is the semi-quantitative urine test, which provides an indication 
of the level of hCG in women’s urine by including multiple sensitivity levels on the same test. 
The tests require interpretation (e.g., to read the current level of hCG and compare it to a pre-
abortion level), so clear instructions are important if women will be using the tests on their 
own (Blum, Shochet, et al., 2012; Lynd et al., 2013). 
Discussion with clinician: Several studies assess the effectiveness of a symptom questionnaire 
or checklist, which is often delivered by clinic staff during a follow-up phone call. Asking women 
about symptoms, including duration of heavy bleeding and ongoing symptoms of pregnancy, 
following medication administration is one way to identify possible incomplete abortions. 
Questionnaire: Like discussions with clinicians, questionnaires typically include standardized 
questions about bleeding following medication administration and whether women think they 
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are still pregnant. However, questionnaires can be delivered by non-clinical staff, or women 
can complete them on their own.  
Combinations of methods: In a large, multi-site retrospective study, Clark and colleagues 
(2010) arranged for women to receive blinded clinical assessments before undergoing 
ultrasonography to confirm complete medication abortions. They constructed five algorithms 
that included different combinations of the following seven indicators: (1) positive results on a 
low-sensitivity urine pregnancy test, (2) not experiencing at least one day of heavy bleeding, (3) 
experiencing less than two days of heavy bleeding, (4) still feeling pregnant, (5) uncertainty 
about still feeling pregnant, (6) exhibiting any pregnancy symptom, and (7) a clinician 
determining before sonography that further evaluation was desirable. The authors concluded 
that screening algorithms that included patients’ observations, a low-sensitivity pregnancy test, 
and non-sonography clinical evaluation were as effective as sonography in identifying women 
who received additional medical intervention (Clark et al., 2010). 
 
Table 4: Alternatives to Returning to Provider’s Office for Follow-Up 
Method Description Considerations 
Laboratory visit 
Women have blood drawn at a 
local lab for serum hCG 
measurement. 
Results go to the provider, who 
must then communicate with the 
patient. 
Follow-up by 
phone or text 
Clinicians or operators contact 
women to screen for possible 
continuing pregnancies. 
Calls can include the ability to 
schedule follow-up appointments 
for those with possible continuing 
pregnancies or other 
complications. 
Self-assessment 
Women complete a 
questionnaire and a urine test, 
and contact the provider only 
if results indicate a possible 
continuing pregnancy or if they 
have concerns. 
Providers are only assured that the 
self-assessment was completed 
when women contact them about 
possible ongoing pregnancies or 
other concerns. 
   
CLINICAL VISITS WITHOUT ULTRASONOGRAPHY 
As noted previously, routine use of pre- and post-abortion ultrasonography can raise costs and 
limit access (Clark, Panton, et al., 2007). A 2011 review concluded that confirmation of 
pregnancy expulsion can come primarily through patient history (e.g., description of bleeding 
since medication administration) and physical examination, and that urine tests could also play 
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a role (Kaneshiro et al., 2011). Substituting the history and physical exam for typical follow-up 
methods can allow providers without ultrasonography equipment to offer medication 
abortions, which is especially important in low-resource settings. 
LABORATORY FOLLOW-UP 
Using pre- and post-abortion serum hCG measures to confirm abortion completion requires 
two in-person visits to a facility for the baseline and post-procedure measurements, but that 
facility could be a community laboratory rather than the office of an abortion provider. As 
Dunn and colleagues note, “multiple clinic visits may jeopardize privacy and be inconvenient 
and costly for women who must travel, miss work or make child-care arrangements” (Dunn et 
al., 2015). Laboratories may be more conveniently located for many women, and may have 
extended hours or allow drop-ins. However, costs may still be high (Grossman & Grindlay, 
2011). This method still requires providers who receive the lab results to contact patients to 
discuss them (Committee on Practice Bulletins—Gynecology and the Society of Family 
Planning, 2014). 
In 2008, Planned Parenthood Federation of America adopted a protocol change that allows its 
clinics to offer women the option of having a serum hCG level drawn at the time of 
mifepristone administration and obtaining a follow-up measure at another site approximately 
one week later (Horning et al., 2012). 
FOLLOW-UP BY CALL OR TEXT 
Some of the studies that contribute to the evidence base for phone follow-up have required 
participants to visit the clinic for follow-up, but have recorded patients’ and/or clinicians’ 
assessments of abortion completion before performing ultrasonography and then comparing 
the assessments to the sonographic images. Studies have also compared phone follow-up to 
clinic follow-up to test the feasibility of offering the remote follow-up alternative, and these 
report on the number of continuing pregnancies detected even when that was not the primary 
outcome being studied. After studies demonstrated that assessments based on history and 
symptoms could assess abortion completeness with a high degree of accuracy, some providers 
began offering women the option of telephone follow-up. Such remote follow-up options 
typically involve administration of a standardized questionnaire (either by nurses or non-
clinical staff), and women whose answers indicate possible continuing pregnancies or other 
complications are instructed to return to the provider’s office or visit another clinical site. 
One large study asked 931 women who attended a follow-up visit seven days after receiving 
mifepristone about their symptoms and whether they thought they had expelled their 
pregnancies, and the clinicians could ask additional questions before recording both their 
opinions and their patients’ opinions as to whether the pregnancies had been expelled. 
Clinicians then performed ultrasounds, and in 99% of the cases in which both the clinician and 
patient thought the pregnancy had been expelled, sonography confirmed that to be the case 
(Rossi, Creinin, & Meyn, 2004). This study, however, only included four abortion failures, 
which is unsurprising given the efficacy of the mifepristone-misoprostol combination. To 
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study a larger number of failed abortions, Jackson and colleagues (2012) conducted a case-
control study involving 53 women who had a retained gestational sac or ongoing pregnancy 
following medication abortion, plus 53 controls whose abortions were successful. While they 
found that subjects with a continuing pregnancy were more likely to have reported minimal 
bleeding and doubt about having expelled their pregnancies, creating a system to identify these 
women solely by these symptoms found only 68% of them. The authors concluded, “An 
objective measure of complete abortion, such as a pregnancy test, is still required” (Jackson et al., 
2012). 
For the studies described in this section, it is important to note that studies involving medication 
abortion rarely (if ever) achieve 100% follow-up with patients, and it is possible that study 
participants lost to follow-up or not communicating with investigators after a protocol’s 
completion had ongoing pregnancies or other outcomes that are not reflected in results.  
In Pittsburgh, Perriera and colleagues (2010) evaluated the use of phone follow-up, in which 
clinicians called women one week after mifepristone administration and asked a standardized 
set of questions, including whether the women thought they had passed their pregnancies. If 
either the patient or clinician did not think the pregnancy had passed, the woman was asked to 
return to the clinic within seven days for an ultrasound. Patients were also instructed to 
perform a high-sensitivity urine pregnancy test 30 days after taking mifepristone, and received 
a second follow-up call about those results. Out of 139 study participants, four were found to 
have continuing pregnancies. One visited the clinic before the first follow-up phone call, two 
were instructed to come to the clinic and received surgical intervention, and one was not 
instructed to return for a visit after the first call but presented for an interim visit at which the 
continuing pregnancy was discovered and treated (Perriera et al., 2010).  
Several studies in the United Kingdom involved the use of low-sensitivity urine pregnancy 
tests. At British Pregnancy Advisory Service clinics, Bracken and colleagues (Bracken, Lohr, et 
al., 2014) instructed half of study participants to take a low-sensitivity urine test two weeks 
after mifepristone administration, and non-clinician phone operators followed up with them 
by phone, text, or online communication. The operators asked about symptoms and the test 
results, and instructed those whose answers indicated possible ongoing pregnancy to schedule 
a clinic visit. The comparison group received the usual instruction to return for a follow-up 
visit; however, they also received high-sensitivity pregnancy tests, which they were instructed 
to take three weeks after mifepristone administration if they missed their follow-up 
appointment. The proportion of participants not completing their scheduled follow-up (either 
by phone/internet or at the clinic) did not differ between groups, and the study found no 
evidence of a difference between groups in ascertainment of ongoing pregnancy (Bracken, 
Lohr, et al., 2014).  
In a study in Moldova and Uzbekistan, women who completed a semi-quantitative urine test 
and standardized checklists two weeks after mifepristone administration also received follow-
up phone calls; this protocol also detected all of the ongoing pregnancies among participants 
who completed follow-up (99.6% of those enrolled) (Platais et al., 2015).  
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In 2010 the Royal Infirmary of Edinburgh (Scotland), the main provider of abortion services 
in its region, began offering women who received medication abortions the option of phone 
follow-up instead of an in-clinic follow-up visit. Women receive a low-sensitivity urine 
pregnancy test to take two weeks after mifepristone administration, and at that time they 
receive a call from a nurse who asks about the duration and nature of bleeding and whether 
pregnancy symptoms continued. Women with a positive test result or symptoms indicating a 
possible ongoing pregnancy are instructed to come in for ultrasonography. An evaluation of 
the service, involving the records of 476 women who chose phone follow-up, found that the 
urine test with phone screening failed to identify one of four ongoing pregnancies that the 
investigators found (Cameron et al., 2012). A larger, more recent database review at the same 
site (involving 943 women’s records) found no false negatives – that is, no woman was 
discovered to have an ongoing pregnancy after having been told at the phone follow-up that 
she did not need to return for further evaluation (Michie & Cameron, 2014).  
SELF-ASSESSMENT 
Researchers are also investigating the use of self-assessment protocols, in which women 
receive tests and information to allow them to determine whether their abortions are 
complete, and they need only communicate with their providers if they have symptoms of 
continuing pregnancy or other concerns. Studies in the US and Vietnam involved a semi-
quantitative urine test on the day of mifepristone administration and another test either one 
week (US) or two weeks (Vietnam) later, and women were instructed on how to interpret their 
results. Women recorded their self-assessments and presented them at a follow-up clinic visit. 
In both studies, women’s interpretations of the tests identified all of the ongoing pregnancies 
detected – one in the US, and 11 in Vietnam (Blum, Shochet, et al., 2012; Lynd et al., 2013).  
A large study in four European countries (with a total of 924 participants) instructed women in 
the self-assessment group to take a semi-quantitative urine test between one and three weeks 
after mifepristone administration, and they received a follow-up call at one month. The self-
assessments with the urine tests failed to detect three of 27 continuing pregnancies found in 
the self-assessment group; these were then discovered in the second trimester. The group 
receiving in-clinic follow-up had no undetected pregnancies (Oppegaard et al., 2015). While 
the authors reported that statistically the remote follow-up method was non-inferior 
(Oppegaard et al., 2015), an editorial accompanying the published study highlights the three 
undetected continuing pregnancies and notes that failing to detect ongoing pregnancies within 
two weeks can be problematic because “second-trimester abortion confers greater risk of 
complications, is less widely available, and in some countries is illegal” (Hickey & Moore, 
2015). 
After receiving requests from patients to not receive follow-up calls, the Royal Infirmary of 
Edinburgh (whose remote follow-up option is described above) introduced a “self-
assessment” option in 2012, allowing women to opt out of receiving the call if they 
understood and felt confident carrying out instructions on how to interpret their low-
sensitivity urine tests and the kinds of symptoms indicating they should call the provider. A 
database review of women choosing self-assessment found eight ongoing pregnancies, and 
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four of those were not detected until the women had missed one or more menstrual periods. 
All four of these women received follow-up termination procedures at between 12 and 22 
weeks of pregnancy. The authors note that providers may be particularly concerned about not 
detecting continuing pregnancies promptly in countries where second-trimester abortions are 
illegal or unavailable (Cameron et al., 2015). 
The World Health Organization recommends that self-assessment be an option for women 
using mifepristone and misoprostol for pregnancies of up to 63 days and in circumstances 
“where women have a source of accurate information and access to a healthcare provider 
should they need or want it at any stage of the process” (WHO, 2015). The guidelines note, 
“There is evidence that the option is safe and effective including in low-literacy, low-resource 
settings” (WHO, 2015).  
FOLLOW-UP CONSIDERATIONS  
It is important to stress that the elimination of routine visits does not mean that women 
should not have access to follow-up medical care if they are experiencing severe pain or 
bleeding or another adverse event. (All the above studies instructed women to access care as 
soon as they experienced problems, rather than waiting for a scheduled follow-up.) When 
alternative follow-up methods are used, women whose results indicate possible incomplete 
abortions will still need to access additional care.  
In all of these studies involving remote follow-up, many more women were flagged for 
needing follow-up than actually needed additional medical intervention for either incomplete 
abortions or for adverse outcomes such as continued heavy bleeding. The number who 
returned to the clinics or other sites for care was still far lower than the total number receiving 
medication abortions, translating to a reduced burden for women as a whole and for providers. 
Women gave remote follow-up methods high marks for acceptability (Bracken, Lohr et al., 
2014; Cameron et al., 2012; Michie & Cameron, 2014; Platais et al., 2015). 
Given that many women who are instructed to return to providers’ offices for follow-up (as 
the FDA label specifies) do not do so, more convenient follow-up methods may be attractive 
as a way to reduce loss to follow up. In addition, many providers use follow-up visits to 
counsel women about contraception and start them on their chosen method, so those who 
make the follow-up visit optional may need to address contraception at a different point in the 
process. 
TELEMEDICINE 
The Institute of Medicine has defined telemedicine as “the use of electronic information and 
communications technologies to provide and support health care when distance separates 
participants;” today, “telemedicine” and “telehealth” are often used interchangeably. 
Telemedicine can provide access to care for residents of rural areas and patients living in 
medically underserved areas. Approximately 10 million patients receive telemedicine services in 
the US each year, although licensure regulations can pose a barrier to the provision of services 
across state lines (National Research Council, 2012).  
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In the US, little published research on use of telemedicine for medication abortion exists; the 
exception is a set of studies on telemedicine abortion in Iowa (Grindlay, Lane, & Grossman, 
2013; Grossman et al., 2013; Grossman, Grindlay, Buchacker, et al., 2011). In 2008, the Iowa 
clinic network Planned Parenthood of the Heartland, which provided 74% of abortions in the 
state that year, began offering medication abortion by telemedicine at clinic sites not staffed by 
physicians (Iowa is one of the states where only physicians may provide medication abortions; 
see “State Level Medication Abortion Policies” on page 28). Clinic staff members take each 
patient’s history, perform an ultrasound, provide information about medication abortion, and 
receive the patient’s informed consent; they then upload the medical history and 
ultrasonographic image to a secure server so the physician can view them. The physician then 
uses video teleconference equipment to have a discussion with the patient. If the patient is 
eligible for a medication abortion, the physician enters a password that remotely unlocks a drawer 
that contains the mifepristone and misoprostol, watches the patient take the mifepristone, and 
provides the remaining instructions (Grossman, Grindlay, Buchacker, et al., 2011). 
A study using follow-up data from 223 telemedicine patients and 226 face-to-face patients in 
Iowa found that the two methods had equivalent success rates and few adverse events 
(Grossman, Grindlay, Buchacker, et al., 2011). A study of data on all abortions in the two years 
before and two years after the telemedicine option was introduced found that the proportion 
of abortions in the clinics that were medical (as compared with surgical) increased, and clinic 
patients had an increased odds of obtaining either form of abortion before 13 weeks’ gestation 
(Grossman et al., 2013). A study that involved interviews with abortion patients and clinic staff 
found that many who chose telemedicine abortions did so because they could visit a closer 
facility and initiate an abortion more quickly. Several cited concerns about taking time off 
work or school, spending money on travel, and explaining their out-of-town trip to others if 
they were to travel long distances to facilities where they could see the physician in person. 
Clinic staff reported increased efficiencies and fewer cancellations and delays related to travel 
in severe weather (Grindlay, Lane, & Grossman, 2013). 
In the 18 states that specifically require physicians who prescribe mifepristone to do so in 
person (Guttmacher Institute, 2015b), telemedicine cannot be used to provide medication 
abortion. 
Women in many countries where abortion is restricted and medication can be imported may 
receive medication abortion via telemedicine from the organization Women on Web. This 
nonprofit, established in 2006 with the aim of increasing access to safe termination of 
pregnancy and improving maternal health, refers website visitors seeking abortions to a 
physician for an interactive online consultation. Women who indicate that they have 
pregnancies of 63 days or fewer (based on their last menstrual period), do not have 
contraindications, and reside in eligible countries can then receive mifepristone and 
misoprostol by mail or courier, as well as information from the organization about medication 
use and possible side effects and complications. Women are advised to have an ultrasound 
before taking the medications to determine gestational duration, and to complete a pregnancy 
test and ultrasound three weeks later. A helpdesk is available seven days a week to provide 
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support throughout the process. A 2011 study of 2,585 women from 88 countries who 
received medication from Women on Web and provided follow-up information found a 
continuing pregnancy rate of 0.9%  (Gomperts et al., 2012).  
MISOPROSTOL-ONLY ABORTIONS 
The mifepristone-misoprostol combination is currently the gold standard for medication 
abortion because it is more effective and has fewer side effects than the alternatives, but 
misoprostol alone is commonly used in settings where mifepristone is unavailable (due to 
either abortion restrictions or mifepristone not being licensed in all countries). Misoprostol is 
licensed as a drug for gastrointestinal conditions in approximately 90 countries, and its low 
price and stability at room temperature make it well-suited for abortions in low-resource 
settings (Winikoff & Sheldon, 2012). Where mifepristone is not available, the World Health 
Organization recommends repeated doses of misoprostol (800 µg administered vaginally or 
sublingually and repeated at intervals of 3-12 hours for up to three doses) (WHO, 2012).  
A 2011 review concluded that misoprostol alone is less effective than the combined regimen 
(Kulier et al., 2011). Since then, randomized controlled trials comparing the mifepristone-
misoprostol combination to misoprostol alone (using the buccal route of administration) have 
provided additional data. In a trial involving 441 women with pregnancies of up to 63 days’ 
gestation in Tunisia and Vietnam, Blum and colleagues found complete abortion without 
surgical evacuation occurred in 78% of the misoprostol-only group and 93% of the 
mifepristone-misoprostol group (Blum, Raghavan, et al., 2012). In a study involving 100 
women with pregnancies of up to 56 days in India, 74% of misoprostol-only patients and 92% 
of mifepristone-misoprostol patients had complete abortions (Dahiya et al., 2012). A trial in 
Vietnam involving 400 women with pregnancies of up to 63 days found complete abortions in 
76% of the misoprostol-only group and 97% of the mifepristone-misoprostol group (Ngoc et 
al., 2011).  
Worldwide, use of misoprostol alone for medication abortions is often off-label or clandestine 
(Winikoff & Sheldon, 2012), and it is difficult to study success rates or complications from 
clandestine home use. While misoprostol is available over-the-counter in many countries, it is 
only available by prescription in the US. Two relatively recent US surveys of women seeking 
abortions found low rates of attempting self-induced abortion: Grossman and colleagues 
(2010) found 4.6% of respondents reported attempting to induce abortion by any means, while 
Jones (2011) found that 1.2% reported using misoprostol to self-induce an abortion, and 1.4% 
reported using other substances.  
Attempts to self-induce abortions may be more common in areas where access to abortion is 
limited. A survey conducted among women seeking abortions at Texas clinics in 2012, after 
new abortion restrictions took effect in the state, found that 7% reported having first tried 
taking something on their own to induce abortion – and that number rose to 12% when 
considering only the clinics near the Texas-Mexico border (Grossman et al., 2014). In Mexico, 
misoprostol is available from pharmacists without a prescription, but the drug does not come 
with instructions on use for abortion. Grossman and colleagues warn that “if women do not 
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have accurate information, they may use ineffective dosages and may not realize the abortion 
failed until much later in pregnancy, forcing them to seek a second-trimester abortion or 
continue the pregnancy and have a child they do not want or feel they cannot care for” 
(Grossman et al., 2014). A 2015 survey of a statewide representative sample of Texas women 
ages 18 – 49 found that 4.1% reported either trying to end a pregnancy on their own or having 
a best friend who they knew or suspected had done so. Based on the survey responses, the 
authors estimate that between 100,000 and 240,000 women in Texas have tried to end a 
pregnancy on their own without medical assistance (Grossman, White, Fuentes, et al., 2015).   
Many advocates believe that all women should have access to the medication abortion method 
with highest efficacy and fewest side effects, mifepristone with misoprostol (Winikoff & 
Sheldon, 2012). However, in the face of increasing barriers that deny many women that ideal, 
some advocates have called for educating US women about the recommended use of 
misoprostol and making that drug more widely available (Coeytaux, Hessini, & Allina, 2015). 
Further research is needed to optimize repeat dosing and interval scheduling in misoprostol-
alone abortions.  
SUMMARY: COMMON PRACTICE VARIATIONS AMONG ABORTION 
PROVIDERS 
The evidence-based protocols most common in current clinical practice involve 200 mg of 
Mifeprex (rather than 600 mg) (Cleland & Smith, 2015) followed by 800 micrograms of 
misoprostol that women take at home rather than in a provider’s office (Clark, Gold, et al., 
2007; Cleland et al., 2013; Wiegerinck et al., 2008). The interval between mifepristone and 
misoprostol dosage and the route of administration may also vary – e.g., a woman may take 
misoprostol buccally and may do so one day after mifepristone rather than two. 
Providers may also offer medication abortions later in pregnancies, with most providers 
currently using 63 days as the cutoff (Jones & Jerman, 2014). Depending on state laws, 
medication abortions may be performed by mid-level providers (also referred to as advanced 
practice clinicians) such as nurse practitioners, certified nurse-midwives, and physician 
assistants. 
Ongoing research is exploring other variations that have the potential to improve access. 
Home use of misoprostol, which eliminates the second of the three visits specified in the FDA 
label, is already common (Clark, Gold, et al., 2007; Cleland et al., 2013; Wiegerinck et al., 
2008); now, researchers are exploring ways to simplify or eliminate the initial visit and follow-
up visit to further reduce barriers (Chong et al., 2015; Gold & Chong, 2015; Swica et al., 2013). 
Provision of medication abortions via telemedicine or by providers not currently offering the 
service would also improve access in areas where it is currently limited. Some advocates also 
suggest the safe and informed use of misoprostol alone for women who lack access to 
abortions with the mifepristone-misoprostol combination. While misoprostol alone is less 
effective than the two-drug combination, its efficacy is still high, and this regimen is used 
extensively in other countries where mifepristone is unavailable.  
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The research described in the preceding section aims to identify practices that can provide 
women with safe and effective abortion care while accommodating their preferences and 
safeguarding their privacy and dignity. Reducing barriers to medication abortion can allow 
more women to receive abortion services early in their pregnancies, when risks are lowest, and 
may also lower costs and improve efficiency. However, several current and proposed policies 
create barriers to the adoption of evidence-based practices. 
CLAIMS ABOUT “REVERSAL” 
Progesterone is a naturally occurring hormone, and synthetic versions of it are used during 
pregnancy for several established and tested clinical purposes. These include prevention of 
preterm birth and supplementing other hormones used in assisted reproductive technologies 
(Grossman, White, Harris, et al., 2015). Some have suggested that progesterone can reverse the 
abortion process after a woman has taken mifepristone by countering its effect.  
However, there is virtually no credible evidence to support this claim. Researchers recently 
conducted a systematic literature review to identify any manuscripts that examined the question of 
medication abortion reversal. Only one article met the inclusion criteria, and its methods are 
highly flawed. This article describes a case series of seven women who received progesterone 
treatment after taking mifepristone at 7-11 weeks; the exact dosage of mifepristone was not noted. 
Patients received progesterone to “reverse” the effects of the mifepristone. At the end of the 
study, one patient had been lost to follow-up, four patients continued their pregnancies and 
delivered at term, and two patients had completed their abortions within three days of taking 
mifepristone. Based on the six patients with data, 67% (95% CI 30-90%) continued the 
pregnancy; assuming the seventh patient aborted, 57% (95% CI 25-84%) continued the pregnancy 
(Grossman, White, Harris, et al., 2015). This rate is within the expected rate of continuing 
pregnancy with mifepristone alone.  
As Grossman and colleagues note, even this lone study is methodologically flawed in a number of 
ways and fails to meet basic human subjects research requirements. First, there is no mention of 
an ethics board or internal review board (IRB) giving approval for the study. Ethically sound 
research involving humans must meet this basic requirement. Second, the study authors did not 
report how many women were excluded from the study because they had already aborted after 
taking mifepristone alone. Failing to include these women in the final proportions of women who 
“reversed” their medication abortions could dramatically alter the study’s findings. Third, there 
were no rigorous research studies (to date) that examined the use of mifepristone alone beyond 56 
days, yet the study team included women up to 11 weeks’ (77 days) gestation and did not make 
any comparisons between their “intervention” and the effects of taking only mifepristone. This 
failure to include relevant enrollment criteria for participants is not only a failure to meet basic 
research requirements but also can impact the outcomes of the study, as women at later gestations 
might be more likely to continue their pregnancies after taking only mifepristone, regardless of 
any intervention.  
In more rigorous studies of taking mifepristone alone, the proportions of participants with 
continuing pregnancies ranged from 8-46% (Grossman, White, Harris, et al., 2015). This finding is 
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important to mention because women who had no additional intervention after taking 
mifepristone (e.g., no progesterone) may have been likely to continue their pregnancies in nearly 
half of all cases, which should not be confused with reversing the effects of mifepristone, as claimed 
by the original study authors.  
STATE-LEVEL MEDICATION ABORTION POLICIES  
The number and type of restrictive abortion policies have been increasing over the last several years. 
For medication abortion specifically, these policies can affect one or more aspects of the medication 
abortion process, including the type of provider allowed to provide medication abortion, the exact 
protocol that must be followed, and the specific guidance that a clinician can provide to a patient.  
PROTOCOL, CLINICIAN, AND TELEMEDICINE RESTRICTIONS 
Many states restrict the way in which women can access medication abortion. As of September 
2015, 38 states allow only licensed physicians to provide medication abortion,2 three states require 
medication abortion to be provided according to the FDA label, and 18 states require that the 
clinician be physically present for the medication abortion process (Guttmacher Institute, 2015b). 
The first type of restriction prohibits mid-level providers, such as physician assistants, nurse 
practitioners, and certified nurse midwives, from prescribing Mifeprex, despite significant 
evidence that these advanced practice clinicians can safely and effectively provide the same quality 
of care as physicians. The second type of restriction prohibits use of any evidence-based 
protocols, including the one most commonly used in the US: a 200-mg dose of mifepristone taken 
at the clinic, followed by an 800-µg dose of misoprostol at home, with a follow-up clinic visit to 
confirm whether the abortion is complete. This particular restriction does not allow for any 
deviation from the protocol currently described in the FDA label, unless FDA approves a label 
change that allows it – or unless a state’s law specifies that certain variations are allowed. Texas 
law HB 2 permits dosage variations described in a recent practice bulletin from the American 
College of Obstetricians and Gynecologists (Texas House Bill 2, 2013), and provisions of this bill 
are the subject of a pending Supreme Court case.3 Costs can be higher when clinics must use the 
higher doses of Mifeprex in the FDA protocol (the drug is not available in generic form) and must 
see women for three visits – or four, in those states that also require a waiting period between the 
first visit and the start of the procedure. 
Another type of restriction effectively prohibits the use of telemedicine for the medication 
abortion process, an option that may become increasingly important if additional clinics providing 
abortion are required to close due to other state laws designed to reduce abortion availability. 
                                                 
2 38 states also allow only licensed physicians to provide surgical abortion. The states only limiting 
a single type of abortion are New Jersey (limits only surgical abortions) and Colorado (limits only 
medication abortions).  
3 As of December 2015. 
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Telemedicine also presents a promising option for women in rural or other health professional 
shortage areas, where travelling to a clinic for multiple visits may require days off from work or 
even overnight stays hundreds of miles from home.  
In the last 15 years, knowledge about safe, effective, and accessible medication abortion practices 
has advanced well beyond where it was when FDA considered the Mifeprex application. States 
that have imposed the restrictions listed above will restrict access to safe abortion care, not 
improve safety or efficacy as supporters of those laws commonly claim. Several lawsuits have 
challenged these restrictions, or are in the process of doing so. Some judges have allowed the 
regulations to go into effect while litigation is pending, while others have halted the laws’ 
implementation. 
REQUIRED COUNSELING ON “REVERSAL”  
In addition to restricting the ways in which providers can offer medication abortion, some states 
have introduced or passed legislation mandating that providers tell patients it may be possible to 
reverse a medication abortion after they have taken the initial dose of drugs. The claim is that if a 
woman is treated with progesterone after taking mifepristone and before taking misoprostol, she 
might halt the abortion process and allow her pregnancy to continue. As previously discussed, this 
claim is not supported by the evidence.  
In April 2015, the Governor of Arizona signed SB 1318 into law, requiring providers to use the 
following language with patients seeking a medication abortion: “It may be possible to reverse the 
effects of a medication abortion if the woman changes her mind but that time is of the essence” 
(Grimes, 2015). The statute also requires the state’s Department of Health Services to list 
“information on and assistance with reversing the effects of a medication abortion” on their 
website. 
The Arizona law has been temporarily enjoined because of a pending lawsuit filed in the federal 
court (Guttmacher Institute, 2015a). However, Arkansas has also passed a law requiring that 
women receive information on reversing abortion (HB 1578), and legislators in Louisiana have 
announced their intention to introduce similar bills (Resnick, 2015; Wilson, 2015).  
The authors of the recent systematic review of evidence on medication abortion reversal cited 
above clearly summarize the implications of the faulty research that the legislation is based on and 
of the laws themselves: 
“The new laws in Arizona and Arkansas have now bypassed the research process, in effect 
making all women who undergo this treatment subjects in an uncontrolled, unmonitored 
experiment. Providing evidence-based care is part of how physicians meet their beneficence-
based obligations to patients, and therefore, it is a moral as well as a clinical mandate to base 
care on accepted scientific fact. The new laws compel physicians to say things that may 
contradict their clinical knowledge and judgment. Some physicians will not be able to do so 
in good conscience.” (Grossman, White, Harris, et al., 2015) 
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POLICY & RESEARCH IMPLICATIONS 
Looking forward, access to safe and effective medication abortion services will continue to be 
influenced by state and federal policy. There are clear areas of needed policy change and ongoing 
research to ensure that women benefit from the best available information and high-quality medical 
care. 
POTENTIAL TO EXPAND ACCESS TO ABORTION CARE THROUGH MEDICATION 
ABORTION 
When Mifeprex first received FDA approval, supporters of abortion care hoped that the 
availability of medication abortion would expand access to all abortion care by allowing clinicians 
who could not or did not want to perform surgical abortions to offer abortion services (Coeytaux 
Hessini, & Allina, 2015; Leeman et al., 2007). However, there is little evidence to show that access to 
abortion care has expanded substantially in underserved areas since the approval of Mifeprex in 2000.  
Immediately following the approval of Mifeprex, provision of medication abortion grew rapidly at 
first but has leveled off in recent years (Jones & Jerman, 2014). While the overall rate of 
medication abortion continues to grow nationally, certain populations may still not experience 
expanded access. Most facilities that offer only medication abortion are located in areas where 
other providers offer surgical abortion, with only a small percentage serving as the sole abortion 
provider in their metropolitan areas (Jones & Jerman, 2014). This analysis suggests that, even as 
the number of abortion providers may be increasing, they are largely serving areas where women 
already had access to care, while women living in areas where there is a lack of providers continue 
to face barriers to access.  
Some studies have examined the barriers to providing medication abortion in settings that 
previously did not perform any type of abortion. For example, at the University of New Mexico 
(UNM), elective abortions (either surgical or medication) were unavailable for the 10 years prior 
to FDA approval of Mifeprex. After adding medication abortion as an on-site service, 85% of 
eligible women who received pregnancy options counseling at UNM chose medication abortion, 
rather than surgical abortion at an external site (Leeman et al., 2007). This study suggests that 
patients may be receptive to obtaining medication abortion services at practices that do not offer 
surgical abortion. However, there may be substantial barriers for providers wishing to add these 
services to their practices, including clinicians’ lack of abortion training or personal or religious 
objections to providing the service (Espey et al., 2011).  
DIRECTIONS FOR FUTURE RESEARCH  
Significant evidence exists on multiple ways to improve medication abortion services, from dosage 
and timing of each drug to new directions for follow-up care. However, some gaps in the research 
persist.  
One area that would benefit from further research is the proportion of medication abortions that 
are complete after the initial dose of misoprostol, versus those that require an additional dose of 
misoprostol for completion. Cases in the latter category are often not included in counts of 
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ongoing pregnancies following medication abortion (Cleland et al., 2013), but women considering 
medication abortion may want to know the likelihood that they will need an additional dose of 
misoprostol to have a complete abortion. 
While the safety and efficacy of medication abortion offered by mid-level providers is well-
documented in other countries, there are few published studies examining MLPs in the US. 
Evidence from practice guidelines supports the ability of MLPs to provide medication abortion 
with equivalent clinical efficacy as their physician peers, but more research would bolster the case 
for allowing MLPs in all states to offer medication abortion services. 
More research into remote follow-up methods and self-assessment could help identify the most 
effective alternatives to multiple in-person visits.  
Information about methods and outcomes of attempted self-induced abortion will be especially 
important as more state-level abortion restrictions take effect. Research into these restrictions, 
some of which is ongoing, will be essential for documenting the impacts on access, costs and 
other hardships, and health for women who seek both medication and surgical abortions. 
Additionally, the existing literature about the potential to “reverse” a medication abortion does 
not support the claim that it can be done, but if policy-makers continue to propose and pass laws 
that require clinicians and/or other health entities to describe reversal, additional research with 
appropriate safeguards should be conducted. Furthermore, research into the impact of restricting 
providers’ interactions with patients by requiring them to discuss reversal merits investigation as well.  
Additional research is also needed to explore the impact that medication abortion has had on 
access to abortion care more generally. The number of abortion providers has declined in recent 
years, as has the abortion rate. How has availability of medication abortion interacted with other 
developments, such as new legal restrictions on abortion care broadly, to affect these trends? Do 
extensive label requirements (provider agreement, rigid protocol, etc.) pose a challenge for uptake 
among providers and decisions by patients? 
ADVOCACY FOR LABEL CHANGE  
Informed by the robust body of evidence regarding the safety and efficacy of mifepristone, 
reproductive health advocates are making a case that current FDA restrictions on distribution of 
the drug make medication abortion far more complicated and heavily medicalized in the United 
States than is necessary to ensure the health and safety of women using the drug. They further 
argue that the drug regimen outlined on the US mifepristone label actually serves as a barrier to 
providing the highest standard of medication abortion care to women. 
The consequences of labeling a drug with outdated information and imposing an overly restrictive 
regimen are far-reaching. The problem is particularly acute in states where politicians have 
interfered with physicians’ authority to practice evidence-based medicine by enacting laws that 
require rigid adherence to the FDA label when prescribing mifepristone. But the label has effects 
in other states as well, lending the appearance of legitimacy to otherwise medically unsupported 
legislative proposals such as those limiting provision of abortion services to physicians or 
requiring a physician’s physical presence when medication abortion services are provided (Foster 
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et al., 2015; Sheldon & Winikoff, 2015). Additionally, although health care providers in most 
states are not required to adhere strictly to the labeled use or regimen for a drug, drug companies 
are prohibited from distributing information that is not consistent with the drug label (Ventola, 
2009), which, in the case of Mifeprex, prevents the company from promoting the best and safest 
way to use the drug. 
PROTOCOL 
In recent years, advocates have begun to call for changes in how FDA regulates the distribution 
and use of mifepristone. In addition to asking the agency to update the drug label to reflect the 
current evidence, they are urging FDA to eliminate unnecessary regulatory barriers so that 
medication abortion can be provided in the ways that are safest, most effective, and most 
responsive to women’s needs. They point out that the restrictions embedded in the mifepristone 
label are not supported by the evidence (Cleland & Smith, 2015) and that no other drug with a 
comparable safety profile is burdened with the kind of restrictions that have been imposed on 
mifepristone (Coeytaux, Hessini, & Allina, 2015). 
Specifically, advocates support updating the mifepristone dose on the drug label to 200 mg, 
which has been shown to be the safest, most effective dose (Cleland & Smith, 2015). They also 
call for the label to state that mifepristone has been shown to be effective when used up to 70 
days gestation instead of the 49 days on the label today (Abbas, Chong, & Raymond, 2015). 
They point out that the label specification that patients make three office visits and complete 
extensive follow up imposes unnecessary medical costs as well as logistical burdens on women 
seeking medication abortions (Cleland & Smith, 2015; Raymond, Grossman, et al., 2015). 
Furthermore, they argue that FDA should eliminate mifepristone’s Risk Evaluation and 
Mitigation Strategy (REMS) and the associated Elements to Assure Safe Use (ETASU), which 
were established based on the regimen used in the clinical trials the agency reviewed at the time 
of the drug’s approval. 
RISK EVALUATION AND MITIGATION STRATEGY (REMS) AND 
ELEMENTS TO ASSURE SAFE USE (ETASU)  
FDA can require a REMS for a drug if it determines that risk management measures are 
necessary to ensure safe use of the drug. The most extensive REMS plans include ETASU 
requirements, which are actions that health care professionals must take before prescribing or 
dispensing the drug. Because FDA recognizes that imposing ETASU requirements has the 
potential to create a barrier to access, it has established provisions to ensure that the REMS is as 
efficient as possible, including stating that ETASU requirements must be commensurate with 
the specific, serious risks listed in the drug labeling and cannot be unduly burdensome on patient 
access to the drug (FDA, 2015). 
The current ETASU requirements for mifepristone include: 
 Limitation of the authority to prescribe mifepristone to providers who have signed 
Prescriber Agreements, even though other licensed health care professionals may be 
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trained to perform all the services necessary to safely provide medication abortion 
(Foster et al., 2015); 
 A requirement that a woman using mifepristone sign an agreement stating that she will 
take the drug according to the label, even though the drug regimen described on the 
label is not the safest and most effective way to use the drug;  
 A requirement that mifepristone be administered in a medical facility, despite research 
showing that offering women the option to self-administer the drug is safe and highly 
acceptable (Gold & Chong, 2015); and 
 Restrictions on dispensation of the drug, requiring that it be dispensed in a medical 
facility – though several other countries permit pharmacy dispensation (Grossman & 
Goldstone, 2015) – and only by providers who have signed Prescriber Agreements.  
Advocates contend there is strong evidence that these requirements are not commensurate with 
mifepristone’s risks and that they do, in fact, create unnecessary barriers to patient access to the 
drug (Cleland & Smith, 2015).  
Without those medically unsupported regulatory hurdles, a wider range of providers would be 
able to offer medication abortion, potentially increasing access for women who are currently not 
able to obtain abortion care. 
 
 
This paper has explored some of the existing research on the medication abortion process. It is 
not meant to be an exhaustive literature review but rather an overview of current evidence and 
its impact on policy. Exchange of accurate scientific and clinical information between 
researchers and policy makers has the potential to help ensure that policies are grounded in 
science. Making the connection between policy and science is critical if we are to promote 
women’s health through improved access to high-quality health care.  
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